Evidence map›Paper›PMID 41019049›Full record

ArticleFrontiers in immunology2025

Impact of

Ronald Heregger, Florian Huemer, Richard Greil, Marina Canadas-Ortega, Gernot Posselt, Marieke E Ijsselsteijn, Christina Plattner, Dietmar Rieder, Zlatko Trajanoski, Anne Krogsdam and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Fusobacterium nucleatum, succinate signaling, and immunotherapy resistance in colorectal cancer: clinical relevance and translational opportunities.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ronald HereggerDepartment of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria.
Florian HuemerDepartment of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria.
Richard GreilDepartment of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria.
Marina Canadas-OrtegaDepartment of Biosciences and Medical Biology, Division of Microbial Infection and Cancer, Paris-Lodron University of Salzburg, Salzburg, Austria.
Gernot PosseltDepartment of Biosciences and Medical Biology, Division of Microbial Infection and Cancer, Paris-Lodron University of Salzburg, Salzburg, Austria.
Marieke E IjsselsteijnDepartment of Pathology, Leiden University Medical Center, Leiden, Netherlands.
Christina PlattnerInstitute of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria.
Dietmar RiederInstitute of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria.
Zlatko TrajanoskiInstitute of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria.
Anne KrogsdamInstitute of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria.
Eckhard KlieserCancer Cluster Salzburg, Salzburg, Austria.
Daniel NeureiterCancer Cluster Salzburg, Salzburg, Austria.
Silja Wessler *Department of Biosciences and Medical Biology, Division of Microbial Infection and Cancer, Paris-Lodron University of Salzburg, Salzburg, Austria.
Lukas Weiss *Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Colorectal cancer (CRC) is a major global health concern. The presence of Methods: A cohort of 107 patients with localized CRC treated between 2005 and 2017 was analyzed, categorizing tumors as Fn-positive (Fn Results: In 45 out of 107 patients (42%) tumors were classified as Fn Discussion: Our findings suggest that Fn contributes to an immunosuppressive microenvironment in CRC, diminishing both antibacterial defense and anti-tumor immunity. Selective elimination of Fn may enhance treatment efficacy and warrants further investigation.

Indexed as

Colorectal NeoplasmsFusobacterium InfectionsFusobacterium nucleatumGene Expression Regulation, NeoplasticAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective StudiesTumor Microenvironmentcolorectal cancerFusobacterium nucleatumimmune cell interactionsimmunosuppressive environmentmicrobiotaRNA-Seqtumor microenvironment

Identifiers

PMID41019049
PMCPMC12460317

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.